Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS EP News Bureau Oct 25, 2023 USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome…
